New approaches to pharmacological treatment of osteoporosis

Bulletin of the World Health Organization

Volumn 81, Issue 9, 2003, Pages 657-664

  Åkesson, Kristina ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

Bone and bones physiopathology; Calcium, Dietary therapeutic use; Fractures pathology; Osteoblasts drug effects; Osteoclasts drug effects enzymology; Osteoporosis, Postmenopausal drug therapy; Osteoporosis drug therapy; Vitamin D therapeutic use

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; CATHEPSIN K; CLODRONIC ACID; CYTOKINE; ESTROGEN; ETIDRONIC ACID; GROWTH FACTOR; IBANDRONIC ACID; PARATHYROID GLAND HORMONE; RALOXIFENE; RISEDRONIC ACID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STRONTIUM; STRONTIUM RANELATE; TIBOLONE; TILUDRONIC ACID; UNCLASSIFIED DRUG; VITAMIN D; ZOLENDRONATE;

DISEASE TREATMENT;

ARTICLE; BONE TURNOVER; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; ESTROGEN THERAPY; HUMAN; OSTEOPOROSIS;

BONE AND BONES; CALCITONIN; CALCIUM, DIETARY; DIPHOSPHONATES; FEMALE; FRACTURES, BONE; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; RISK FACTORS; VITAMIN D;

EID: 0141989663     PISSN: 00429686     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. World Health Organization. Assessment of osteoporotic fracture risk and its role in screening for postmenopausal osteoporosis. Geneva: WHO; 1994.
2. Hayden JM, Mohan S, Baylink DJ. The insulin-like growth factor system and the coupling of formation to resorption. Bone 1995;17 2 Suppl:93S-8S.
3. Chapuy MC, Arlot ME, Duboeuf F, Brun J, Crouzet B, Arnaud S, et al. Vitamin D3 and calcium to prevent hip fractures in the elderly women. New England Journal of Medicine 1992;327:1637-42.
4. Bischoff HA, Stahelin HB, Dick W, Akos R, Knecht M, Salis C, et al. Effects of vitamin D and calcium supplementation on falls: a randomized controlled trial. Journal of Bone and Mineral Research 2003;18:343-51.
5. Trivedi DP, Doll R, Khaw KT. Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial. BMJ 2003;326:469.
6. Fleisch H. Bisphosphonates in bone disease. From the laboratory to the patient. London: Academic Press; 2000.
7. Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998;280:2077-82.
8. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996;48:1535-41.
9. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999;282:1344-52.
10. Reginster J, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporosis International 2000;11:83-91.
11. McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. New England Journal of Medicine 2001;344:333-40.
12. Brown JP, Kendler DL, McClung MR, Emkey RD, Adachi JD, Bolognese MA, et al. The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcified Tissue International 2002;71:103-11.
13. Schnitzer T, Bone HG, Crepaldi G, Adami S, McClung M, Kiel D, et al. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group 15. Aging (Milano) 2000;12:1-12.
14. Thiebaud D, Burckhardt P, Kriegbaum H, Huss H, Mulder H, Juttmann JR, et al. Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis. American Journal of Medicine 1997;103:298-307.
15. Reid IR, Brown JP, Burckhardt P, Horowitz Z, Richardson P, Trechsel U, et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. New England Journal of Medicine 2002;346:653-61.
16. Chesnut CH 3rd, Silverman S, Andriano K, Genant H, Gimona A, Harris S, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Groericanup. American Journal of Medicine 2000;109:267-76.
17. Ljunghall S, Gardsell P, Johnell O, Larsson K, Lindh E, Obrant K, et al. Synthetic human calcitonin in postmenopausal osteoporosis: a placebo-controlled, double-blind study. Calcified Tissue International 1991;49:17-9.
18. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999;282:637-45.
19. Cauley JA, Norton L, Lippman ME, Eckert S, Krueger KA, Purdie DW, et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Research and Treatment 2001;65:125-34.
20. Barrett-Connor E, Grady D, Sashegyi A, Anderson PW, Cox DA, Hoszowski K, et al. Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA 2002;287:847-57.
21. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33.
22. Beardsworth SA, Kearney CE, Purdie DW. Prevention of postmenopausal bone loss at lumbar spine and upper femur with tibolone: a two-year randomised controlled trial. British Journal of Obstetrics and Gynaecology 1999;106:678-83.
23. Berning B, Kuijk CV, Kuiper JW, Bennink HJ, Kicovic PM, Fauser BC. Effects of two doses of tibolone on trabecular and cortical bone loss in early postmenopausal women: a two-year randomized, placebo-controlled study. Bone 1996;19:395-9.
24. Roux C, Pelissier C, Fechtenbaum J, Loiseau-Peres S, Benhamou CL. Randomized, double-masked, 2-year comparison of tibolone with 17beta-estradiol and norethindrone acetate in preventing postmenopausal bone loss. Osteoporosis International 2002;13:241-8.
25. Cann CE, Roe EB, Sanchez SD, Amaud CD. PTH effects in the femur: envelope-specific responses by 3DQCT in postmenopausal women. Journal of Bone and Mineral Research 1999;14:S137.
26. Mosekilde L, Danielsen CC, Sogaard CH, McOsker JE, Wronski TJ. The anabolic effects of parathyroid hormone on cortical bone mass, dimensions and strength - assessed in a sexually mature, ovariectomized rat model. Bone 1995;16:223-30.
27. Zanchetta JR, Bogado C, Ferretti JL, Wang O, Sato M, Gaich GA. Effects of LY333334 (Recombinant parathyroid hormone (1-34)) on cortical bone strength indices as assessed by peripheral quantitative computed tomography. Program and abstracts of the 1st Joint Meeting of the International Bone and Mineral Society and the European Calcified Tissue Society; June 5-10, 2001; Madrid, Spain. Bone 2001;28 Suppl:S86.
28. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. New England Journal of Medicine 2001;344:1434-41.
29. Lindsay R, Nieves J, Formica C, Henneman E, Woelfert L, Shen V, et al. Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 1997;350:550-5.
30. Rittmaster RS, Bolognese M, Ettinger MP, Hanley DA, Hodsman AB, Kendler DL, et al. Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. Journal of Clinical Endocrinology and Metabolism 2000;85:2129-34.
31. Body JJ, Gaich GA, Scheele WH, Kulkarni PM, Miller PD, Peretz A, et al. A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis. Journal of Clinical Endocrinology and Metabolism 2002;87:4528-35.
32. Marie PJ, Hott M, Modrowski D, De Pollak C, Guillemain J, Deloffre P, et al. An uncoupling agent containing strontium prevents bone loss by depressing bone resorption and maintaining bone formation in estrogen-deficient rats. Journal of Bone and Mineral Research 1993;8:607-15.
33. Su Y, Bonet J, Deloffre P, Tsouderos Y, Baron R. The strontium salt S12911 inhibits bone resorption in mouse calvaria and isolated rat osteoclast cultures. Journal of Bone and Mineral Research 1992;17 Suppl 1:188.
34. Boivin G, Deloffre P, Perrat B, Panczer G, Boudeulle M, Mauras Y, et al. Strontium distribution and interactions with bone mineral in monkey iliac bone after strontium salt (S 12911) administration. Journal of Bone and Mineral Research 1996;11:1302-11.
35. Meunier PJ, Slosman DO, Delmas PD, Sebert JL, Brandi ML, Albanese C, et al. Strontium ranelate: dose-dependent effects in established postmenopausal vertebral osteoporosis - a 2-year randomized placebo controlled trial. Journal of Clinical Endocrinology and Metabolism 2002;87:2060-6.
36. Bekker PJ, Holloway D, Nakanishi A, Arrighi M, Leese PT, Dunstan CR. The effect of a single dose of osteoprotegerin in postmenopausal women. Journal of Bone and Mineral Research 2001;16:348-60.
37. Drake FH, Dodds RA, James IE, Connor JR, Debouck C, Richardson S, et al. Cathepsin K, but not cathepsins B, L, or S, is abundantly expressed in human osteoclasts. Journal of Biological Chemistry 1996;271:12511-6.
38. Gelb BD, Shi GP, Chapman HA, Desnick RJ. Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency. Science 1996;273:1236-8.
39. Dimai HP, Müller T, Eder S, Hermann J. Effects of the TNF-alfa antibody imfliximab on serum markers of bone turnover and mineral metabolism in patients with rheumatoid arthritis. Bone 2001;28:S179.
40. Deng HW, Stegman MR, Davies KM, Conway T, Recker RR. Genetic determination of variation and covariation of peak bone mass at the hip and spine. Journal of Clinical Densitometry 1999;2:251-63.
41. Ensrud KE, Stone K, Cauley JA, White C, Zmuda JM, Nguyen TV, et al. Vitamin D receptor gene polymorphisms and the risk of fractures in older women. For the Study of Osteoporotic Fractures Research Group. Journal of Bone and Mineral Research 1999;14:1637-45.
42. Gerdhem P, Brändström H, Stiger F, Obrant K, Melhus H, Ljunggren O, et al. Association of collagen type 1 (COL1A1) Sp 1 polymorphism with femoral neck bone mineral density and wrist fracture in elderly women. Calcified Tissue International 2003 (forthcoming).